Medscape speaks to experts including Lindsay S. Lally, MD, rheumatologist at HSS about prescribing avacopan as an adjunctive treatment for severe, active antineutrophil cytoplasmic autoantibody (ANCA)–associated vasculitis (AAV). 

Many rheumatologists are likely familiar with avacopan, but are not used to prescribing it, explained Dr. Lally. 

"Rituximab was approved for GPA (granulomatosis with polyangiitis) and MPA (microscopic polyangiitis) a decade ago at this point. It was a drug that we as rheumatologists were used to using. We used it for other indications. Avacopan is a totally new drug, a new mechanism of action, so there's not a lot of extractable data that we have in terms of comfort with the drug, and so I think that's one of the biggest hurdles," she said.

Read the full article at medscape.com.